vs
Side-by-side financial comparison of Evolus, Inc. (EOLS) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $73.1M, roughly 1.0× Evolus, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 6.7%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 4.6%).
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
EOLS vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.1M | $75.5M |
| Net Profit | $-10.7M | — |
| Gross Margin | 66.9% | 69.3% |
| Operating Margin | 23.8% | 22.7% |
| Net Margin | -14.6% | — |
| Revenue YoY | 6.7% | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.16 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $73.1M | — | ||
| Q4 25 | $90.3M | $75.5M | ||
| Q3 25 | $69.0M | $54.5M | ||
| Q2 25 | $69.4M | $52.4M | ||
| Q1 25 | $68.5M | $46.0M | ||
| Q4 24 | $78.9M | $59.1M | ||
| Q3 24 | $61.1M | $80.5M | ||
| Q2 24 | $66.9M | $47.1M |
| Q1 26 | $-10.7M | — | ||
| Q4 25 | $130.0K | — | ||
| Q3 25 | $-15.7M | $8.8M | ||
| Q2 25 | $-17.1M | $5.9M | ||
| Q1 25 | $-18.9M | $3.0M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-19.2M | $20.3M | ||
| Q2 24 | $-11.3M | $-4.5M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 65.7% | 69.3% | ||
| Q3 25 | 66.5% | 77.7% | ||
| Q2 25 | 65.3% | 76.5% | ||
| Q1 25 | 68.1% | 77.1% | ||
| Q4 24 | 66.7% | 76.4% | ||
| Q3 24 | 68.9% | 63.9% | ||
| Q2 24 | 70.3% | 77.4% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 4.7% | 22.7% | ||
| Q3 25 | -16.7% | 17.6% | ||
| Q2 25 | -14.7% | 12.7% | ||
| Q1 25 | -22.1% | 8.7% | ||
| Q4 24 | -2.9% | 22.6% | ||
| Q3 24 | -25.3% | 27.4% | ||
| Q2 24 | -11.5% | -4.6% |
| Q1 26 | -14.6% | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | -22.8% | 16.2% | ||
| Q2 25 | -24.7% | 11.2% | ||
| Q1 25 | -27.6% | 6.5% | ||
| Q4 24 | -8.6% | — | ||
| Q3 24 | -31.4% | 25.2% | ||
| Q2 24 | -17.0% | -9.6% |
| Q1 26 | $-0.16 | — | ||
| Q4 25 | $0.01 | $0.26 | ||
| Q3 25 | $-0.24 | $0.17 | ||
| Q2 25 | $-0.27 | $0.12 | ||
| Q1 25 | $-0.30 | $0.06 | ||
| Q4 24 | $-0.11 | $0.40 | ||
| Q3 24 | $-0.30 | $0.41 | ||
| Q2 24 | $-0.18 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.8M | $97.5M |
| Total DebtLower is stronger | $156.4M | $22.7M |
| Stockholders' EquityBook value | — | $130.3M |
| Total Assets | $220.6M | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $49.8M | — | ||
| Q4 25 | $53.8M | $97.5M | ||
| Q3 25 | $43.5M | $94.4M | ||
| Q2 25 | $61.7M | $96.0M | ||
| Q1 25 | $67.9M | $93.2M | ||
| Q4 24 | $87.0M | $101.0M | ||
| Q3 24 | $85.0M | $96.7M | ||
| Q2 24 | $93.7M | $96.8M |
| Q1 26 | $156.4M | — | ||
| Q4 25 | $146.1M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | $121.8M | $56.7M | ||
| Q4 24 | $121.5M | $68.0M | ||
| Q3 24 | $121.2M | $79.3M | ||
| Q2 24 | $120.9M | $90.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-23.1M | $130.3M | ||
| Q3 25 | $-28.8M | $115.3M | ||
| Q2 25 | $-18.7M | $104.7M | ||
| Q1 25 | $-6.6M | $97.1M | ||
| Q4 24 | $5.5M | $92.1M | ||
| Q3 24 | $5.9M | $71.1M | ||
| Q2 24 | $19.3M | $48.5M |
| Q1 26 | $220.6M | — | ||
| Q4 25 | $225.9M | $216.3M | ||
| Q3 25 | $219.0M | $202.9M | ||
| Q2 25 | $228.8M | $194.9M | ||
| Q1 25 | $213.4M | $196.2M | ||
| Q4 24 | $232.6M | $213.3M | ||
| Q3 24 | $229.6M | $220.7M | ||
| Q2 24 | $233.8M | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 22.00× | 0.74× | ||
| Q3 24 | 20.58× | 1.12× | ||
| Q2 24 | 6.26× | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $12.8M | $14.4M | ||
| Q3 25 | $-14.7M | $9.7M | ||
| Q2 25 | $-24.8M | $14.1M | ||
| Q1 25 | $-15.6M | $3.6M | ||
| Q4 24 | $4.8M | $15.6M | ||
| Q3 24 | $-5.7M | $11.0M | ||
| Q2 24 | $-6.5M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $11.3M | $14.4M | ||
| Q3 25 | $-15.6M | $9.7M | ||
| Q2 25 | $-25.5M | $14.1M | ||
| Q1 25 | $-16.0M | $3.6M | ||
| Q4 24 | $4.4M | $15.6M | ||
| Q3 24 | $-6.0M | $11.0M | ||
| Q2 24 | $-6.9M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | 19.1% | ||
| Q3 25 | -22.7% | 17.7% | ||
| Q2 25 | -36.7% | 26.8% | ||
| Q1 25 | -23.3% | 7.7% | ||
| Q4 24 | 5.5% | 26.4% | ||
| Q3 24 | -9.9% | 13.7% | ||
| Q2 24 | -10.4% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 0.0% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 98.67× | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EOLS
| Product revenue, net | $72.7M | 99% |
| Service revenue | $390.0K | 1% |
PBYI
Segment breakdown not available.
